Edward M. MD Kaye - 01 Dec 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role: CEO, Director
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol: STOK
Transactions as of: 01 Dec 2024
Transactions value $: $0
Form type: 4
Date filed: 03 Dec 2024, 16:13
Previous filing: 03 Oct 2024
Next filing: 10 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STOK	Common Stock	Options Exercise	$0	+21.6K	+79.97%	$0.00	48.6K	01 Dec 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STOK	Restricted Stock Unit (RSU)	Options Exercise	$0	-21.6K	-83.34%	$0.00	4.32K	01 Dec 2024	Common Stock	21.6K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2	21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.